Levomilnacipran Hydrochloride
Brand Names: Fetzima
Methodology & AI Transparency ⓘ
Levomilnacipran Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage fetzima: ® is indicated for the treatment of major depressive disorder (MDD) in adults .
- 2 Real-world patient consensus: 86% patient "Worth It" rating across 19 anonymous logs for Levomilnacipran Hydrochloride (RxNorm 1433217).
- 3 Typical cash cost range: Public pharmacy ledger: $185.00 low cash benchmark vs. $453.25 chain retail average ($16.7921/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Levomilnacipran Hydrochloride tolerability events: nausea (11.4%), constipation (5.9%), vomiting (5%).
Ask our AI Specialists anything about Levomilnacipran Hydrochloride
Levomilnacipran Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage fetzima: ® is indicated for the treatment of major depressive disorder (MDD) in adults . Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established. FETZIMA is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD) in adults ( 1 ). Limitation of Use : FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established ( 1 ).
12.1 Mechanism of Action The exact mechanism of the antidepressant action of levomilnacipran is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Non-clinical studies have shown that levomilnacipran is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).
Pharmacokinetic profiling of Levomilnacipran Hydrochloride demonstrates an elimination half-life of Approximately 9–17 hours terminal plasma half-life for Levomilnacipran Hydrochloride with Estimated 57%–69% oral systemic absorption for Levomilnacipran Hydrochloride systemic bioavailability; clearance proceeds via hepatic oxidation via cyp3a4 followed by renal and biliary excretion of levomilnacipran hydrochloride metabolites, reaching clinical onset within peak plasma concentration (tmax) reached 1–4 hours post-dose for levomilnacipran hydrochloride.
Titration schedules for Levomilnacipran Hydrochloride (40 mg/1 Capsule, Extended Release → Kit → 20 mg/1 Capsule, Extended Release → 120 mg/1 Capsule, Extended Release → 80 mg/1 Capsule, Extended Release) require excluding 4 contraindications fetzima is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran hcl, or to any excipient in the formulation.; prior anaphylaxis, angioedema, or severe hypersensitivity to levomilnacipran hydrochloride or levomilnacipran hydrochloride excipients; real-world patient logs highlight nausea (11.4% of reports), headache (6.9% of reports), dizziness (6.1% of reports) alongside a 86.00% Worth-It consensus.
Combining Levomilnacipran Hydrochloride with MAOIs within a 14-day washout window risks severe serotonergic or pressor toxicity.
Potent CYP3A4 modulators alter hepatic clearance of Levomilnacipran Hydrochloride, shifting steady-state plasma concentrations.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS FETZIMA is contraindicated: in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation.
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Levomilnacipran Hydrochloride or Levomilnacipran Hydrochloride excipients
Logged Side-Effect Incidence (19 Reports)
Levomilnacipran Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Levomilnacipran Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Safety and real-world benefits of Levomilnacipran Extended Release in children Conclusions: The high placebo response in this study prevented the detection of an effect of levomilnacipran in children and adolescents. Journal of child and adolescent psychopharmacology • 2024-06-15 • Phase III Randomized Trial | N = 134 | 88/100 | PMID 38700708 ↗ |
Levomilnacipran Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $16.7921/unit (~$503.76/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
| Hims & Hers Direct Cash Pharmacy (Licensed Telehealth Cash Program) | State-licensed clinician review • ~2d mail fulfillment | $49.00/mo program | Program details |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
Levomilnacipran Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Levomilnacipran Hydrochloride RxNorm Concept ID | 1433217 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $16.7921 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Levomilnacipran Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Levomilnacipran Hydrochloride integrating DailyMed SPL (2024-04-30), CMS NADAC ($16.7921/unit), and 19 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Levomilnacipran Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.